← Back to Search

NMDA Receptor Antagonist

Intravenous ketamine for Depression

Phase 1 & 2
Waitlist Available
Research Sponsored by Rebecca Price
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up trajectories from 24 hours through month 12 post-infusion, month 12 reported
Awards & highlights

Study Summary

This trial will test how well ketamine + cognitive training works for depression, compared to ketamine or cognitive training alone. They will look at 3 primary outcomes related to brain function and 1 primary outcome related to depression severity.

Eligible Conditions
  • Depression

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~trajectories from 24 hours through month 12 post-infusion, month 12 reported
This trial's timeline: 3 weeks for screening, Varies for treatment, and trajectories from 24 hours through month 12 post-infusion, month 12 reported for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Cognitive Flexibility
Executive-salience Network Functional Connectivity
Implicit Self-representations
+2 more
Secondary outcome measures
Affective Flexibility
Cognitive Flexibility Scale
Cognitive Triad Inventory
+12 more

Side effects data

From 2022 Phase 1 & 2 trial • 154 Patients • NCT03237286
97%
dissociative effects
68%
dizziness
39%
dry mouth
30%
nausea
17%
restlessness
17%
sweating
17%
headache
16%
decreased energy
12%
increased appetite
11%
palpitations
10%
anxiety
8%
emotional indifference
7%
elevated blood pressure
6%
tremors
5%
difficulty sleeping: too much
4%
emesis
3%
elevated heart rate
2%
difficulty focusing vision
2%
loss of sexual desire
1%
feeling "discombobulated"
1%
difficulty urinating
1%
feeling "high" (per verbal report)
1%
difficulty sleeping: too little
1%
increased weight
1%
lowered pulse
1%
tinnitus
1%
suicidal ideation
100%
80%
60%
40%
20%
0%
Study treatment Arm
Ketamine
Saline

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Ketamine + Cognitive TrainingExperimental Treatment2 Interventions
Group II: Ketamine + Sham TrainingPlacebo Group1 Intervention
Group III: Saline + Cognitive TrainingPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Intravenous ketamine
2017
Completed Phase 2
~160
Computer-based Cognitive Training
2017
Completed Phase 2
~200

Find a Location

Who is running the clinical trial?

Rebecca PriceLead Sponsor
6 Previous Clinical Trials
514 Total Patients Enrolled
2 Trials studying Depression
83 Patients Enrolled for Depression
National Institute of Mental Health (NIMH)NIH
2,783 Previous Clinical Trials
2,688,973 Total Patients Enrolled
665 Trials studying Depression
251,280 Patients Enrolled for Depression

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Pennsylvania
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
Journal of Abnormal PsychologyJournal
Repeated Measurement of Implicit Self-associations in Clinical Depression: Psychometric, Neural, and Computational Properties.
Price, Rebecca B., Benjamin Panny, Michelle Degutis, and Angela Griffo. 2021. “Repeated Measurement of Implicit Self-associations in Clinical Depression: Psychometric, Neural, and Computational Properties.”. Journal of Abnormal Psychology. American Psychological Association (APA). doi:10.1037/abn0000651.
clinicaltrials.govStudy
Intravenous Ketamine Plus Neurocognitive Training for Depression
Rebecca Price 2017. "Intravenous Ketamine Plus Neurocognitive Training for Depression". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03237286.
~21 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top